<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00729079</url>
  </required_header>
  <id_info>
    <org_study_id>24895</org_study_id>
    <nct_id>NCT00729079</nct_id>
  </id_info>
  <brief_title>Diabetes Prevention Program Pilot Study</brief_title>
  <acronym>DPP</acronym>
  <official_title>Virtual Translation of Diabetes Prevention to Primary Care: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study is intended to demonstrate that we can actually deliver the Diabetes&#xD;
      Prevention Program intervention well and to show that it is likely effective. We will use&#xD;
      results from this pilot study to support our application to The National Institute of Health.&#xD;
      NIH is asking for health care centers to show ways to provide this treatment at a reasonable&#xD;
      cost. We propose to demonstrate successful and sustainable use DPP's lifestyle intervention&#xD;
      in a primary care health care setting (University of Rochester Primary Care).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome measure is weight loss with a goal of 7% of initial weight.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exercising a minimum of 150 minutes per week at a moderate level to maintain an energy expenditure of 700 kcals per week</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>;Fat intake less than 25% and saturated fat less than 10% Fiber intake of at least 25 grams per day;Fasting blood sugar &lt; 100 mg/dL; Absence of tobacco use</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Diabetes Prevention</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject will be randomly assigned to work with providers at Clinton Medical Associates</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be randomly assigned to work with providers at 1655 Elmwood AVe, Suite 125</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>DPP</intervention_name>
    <description>The primary outcome measure is weight loss with a goal of 7% of initial weight.&#xD;
Secondary outcomes are adherence to behavior changes:&#xD;
Exercising a minimum of 150 minutes per week at a moderate level to maintain an energy expenditure of 700 kcals per week&#xD;
Fat intake less than 25% and saturated fat less than 10%&#xD;
Fiber intake of at least 25 grams per day&#xD;
Fasting blood sugar &lt; 100 mg/dL&#xD;
Absence of tobacco use</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>DPP</intervention_name>
    <description>The primary outcome measure is weight loss with a goal of 7% of initial weight.&#xD;
Secondary outcomes are adherence to behavior changes:&#xD;
Exercising a minimum of 150 minutes per week at a moderate level to maintain an energy expenditure of 700 kcals per week&#xD;
Fat intake less than 25% and saturated fat less than 10%&#xD;
Fiber intake of at least 25 grams per day&#xD;
Fasting blood sugar &lt; 100 mg/dL&#xD;
Absence of tobacco use</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  BMI &gt;24 kg/m2 (&gt;22 kg/m2 among Asian Americans)&#xD;
&#xD;
          -  IGT (2-h plasma glucose 140~199 mg/dl based on 75-g OGTT if available). The OGTT will&#xD;
             not be required for inclusion, but the CMA practitioners may wish to recommend the&#xD;
             OGTT for their patients.&#xD;
&#xD;
          -  Elevated FPG (95~125 mg/dl*).&#xD;
&#xD;
          -  HDL-triglyceride ration &gt; 3.5.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetes at baseline&#xD;
&#xD;
          -  FPG &gt;126 mg/dl*&#xD;
&#xD;
          -  2-h plasma glucose &gt;200 mg/dl based on 75-g OGTT, if available. OGTT will not be&#xD;
             required (see above note).&#xD;
&#xD;
          -  Diabetes diagnosed by a physician and confirmed by other clinical data, other than&#xD;
             during pregnancy.&#xD;
&#xD;
          -  Ever used antidiabetic medication, other than during pregnancy&#xD;
&#xD;
          -  Medical conditions likely to limit life span and/or increase risk of intervention&#xD;
&#xD;
          -  Cardiovascular disease&#xD;
&#xD;
          -  Hospitalization for treatment of heart disease in past 6 months New York Heart&#xD;
             Association Functional Class&gt; 2&#xD;
&#xD;
          -  Left bundle branch block or third degree AV block Aortic stenosis&#xD;
&#xD;
          -  Systolic blood pressure&gt; 180 mmHg or diastolic blood pressure&gt; 105 mmHg&#xD;
&#xD;
          -  Cancer requiring treatment in the past 5 years, unless the prognosis is considered&#xD;
             good&#xD;
&#xD;
          -  Renal disease (creatinine GFR &lt; or = 30 ml/hr or &gt; 2.0 mg/dl if GFR not available).&#xD;
&#xD;
          -  Anemia (hematocrit &lt;36% in men or &lt;33% in women)&#xD;
&#xD;
          -  Hepatitis (based on history or serum transaminase elevation)&#xD;
&#xD;
          -  Other gastrointestinal disease (pancreatitis, acute inflammatory bowel disease)&#xD;
&#xD;
          -  Recent or significant abdominal surgery&#xD;
&#xD;
          -  Pulmonary disease with dependence on oxygen or daily use of bronchodilators&#xD;
&#xD;
          -  Chronic infection (e.g., HIV, active tuberculosis)&#xD;
&#xD;
          -  Conditions or behaviors likely to affect conduct of the trial&#xD;
&#xD;
          -  Unable to communicate with clinic staff (e.g., read and speak English).&#xD;
&#xD;
          -  Unwilling to accept treatment assignment by randomization&#xD;
&#xD;
          -  Participation in another intervention research project that might interfere with DPP&#xD;
&#xD;
          -  Weight loss of &gt; 10% in past 6 months for any reason except postpartum weight loss&#xD;
&#xD;
          -  Unable to walk 0.25 miles in 10 min&#xD;
&#xD;
          -  Currently pregnant or within 3 months postpartum&#xD;
&#xD;
          -  Currently nursing or within 6 weeks of having completed nursing&#xD;
&#xD;
          -  Pregnancy anticipated during the course of the trial&#xD;
&#xD;
          -  Unwilling to undergo pregnancy testing or report possible pregnancy promptly&#xD;
&#xD;
          -  Unwilling to take adequate contraceptive measures, if potentially fertile&#xD;
&#xD;
          -  Major psychiatric disorder, including severe active major depression, severe anxiety,&#xD;
             schizophrenia, manic depression, bi-polar disorder&#xD;
&#xD;
          -  Excessive alcohol intake, either acute or chronic&#xD;
&#xD;
          -  Medications and medical conditions likely to confound the assessment for diabetes&#xD;
             including:&#xD;
&#xD;
               -  Niacin, in doses indicated for lowering serum triglycerides&#xD;
&#xD;
               -  Glucocorticoids, systemic&#xD;
&#xD;
          -  Other prescription weight-loss medications&#xD;
&#xD;
          -  Active Thyroid disease, suboptimally treated as indicated by abnormal serum&#xD;
             thyroid-stimulating hormone&#xD;
&#xD;
          -  Other endocrine disorders (e.g., Cushing's syndrome, acromegaly)&#xD;
&#xD;
          -  Fasting plasma triglyceride &gt;600 mg/dl, despite treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geoffrey C Williams, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University ofRochester</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Heather Patrick, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinton Medical Associated</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Therapeutic Lifestyle Changes</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bsc.gwu.edu/dpp/manuals.htmlvdoc</url>
    <description>Diabetes Prevention Program</description>
  </link>
  <reference>
    <citation>American Diabetes Association. Standards of medical care in diabetes--2008. Diabetes Care. 2008 Jan;31 Suppl 1:S12-54. doi: 10.2337/dc08-S012.</citation>
    <PMID>18165335</PMID>
  </reference>
  <reference>
    <citation>Benjamin SM, Valdez R, Geiss LS, Rolka DB, Narayan KM. Estimated number of adults with prediabetes in the US in 2000: opportunities for prevention. Diabetes Care. 2003 Mar;26(3):645-9.</citation>
    <PMID>12610015</PMID>
  </reference>
  <reference>
    <citation>Goldstein MG, Whitlock EP, DePue J; Planning Committee of the Addressing Multiple Behavioral Risk Factors in Primary Care Project. Multiple behavioral risk factor interventions in primary care. Summary of research evidence. Am J Prev Med. 2004 Aug;27(2 Suppl):61-79. Review.</citation>
    <PMID>15275675</PMID>
  </reference>
  <reference>
    <citation>Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, Hamman RF, Ackermann RT, Engelgau MM, Ratner RE; Diabetes Prevention Program Research Group. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med. 2005 Mar 1;142(5):323-32.</citation>
    <PMID>15738451</PMID>
  </reference>
  <reference>
    <citation>Maciosek MV, Edwards NM, Coffield AB, Flottemesch TJ, Nelson WW, Goodman MJ, Solberg LI. Priorities among effective clinical preventive services: methods. Am J Prev Med. 2006 Jul;31(1):90-6. Review.</citation>
    <PMID>16777547</PMID>
  </reference>
  <reference>
    <citation>Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001 May 3;344(18):1343-50.</citation>
    <PMID>11333990</PMID>
  </reference>
  <reference>
    <citation>Westfall JM, Mold J, Fagnan L. Practice-based research--&quot;Blue Highways&quot; on the NIH roadmap. JAMA. 2007 Jan 24;297(4):403-6.</citation>
    <PMID>17244837</PMID>
  </reference>
  <reference>
    <citation>Williams GC, Grow VM, Freedman ZR, Ryan RM, Deci EL. Motivational predictors of weight loss and weight-loss maintenance. J Pers Soc Psychol. 1996 Jan;70(1):115-26.</citation>
    <PMID>8558405</PMID>
  </reference>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>August 1, 2008</study_first_submitted>
  <study_first_submitted_qc>August 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2008</study_first_posted>
  <last_update_submitted>October 8, 2015</last_update_submitted>
  <last_update_submitted_qc>October 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Geoffrey Williams</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Diabetes Prevention</keyword>
  <keyword>Pre-Diabetes</keyword>
  <keyword>Exercise</keyword>
  <keyword>Fat Intake</keyword>
  <keyword>Fasting blood sugar</keyword>
  <keyword>tobacco cessation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

